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Abstract
Background: Chemotherapy-induced cell death can involve the induction of apoptosis. Thus,
aberrant function of the pathways involved might result in chemoresistance. Since cell adhesion to
the extracellular matrix acts as a survival factor that homeostatically maintains normal tissue
architecture, it was tested whether acquisition of resistance to deadhesion-induced apoptosis
(anoikis) in human osteosarcoma would result in resistance to chemotherapy.
Methods:  Osteosarcoma cell lines (SAOS-2 and TE-85) obtained from ATCC and were
maintained in complete Eagle's MEM medium. Suspension culture was established by placing cells in
tissue culture wells coated with poly-HEMA. Cell cytotoxicity was determined using a live/dead
cytotoxicity assay. Cell cycle/apoptosis analyses were performed using propidium iodide (PI)
staining with subsequent FACS analysis. Apoptosis was also assayed by Annexin-FITC/PI staining.
Results: Etoposide, adriamycin, vinblastine, cisplatin and paclitaxel were able to induce apoptosis
in human osteosarcoma cells SAOS-2 regardless of their anoikis resistance phenotype or the
culture conditions (adhered vs. suspended). Moreover, suspended anoikis resistant TE-85 cells (TE-
85ar) retained their sensitivity to chemotherapy as well.
Conclusion: Acquisition of anoikis resistance in human osteosarcoma cells does not result in a
generalized resistance to all apoptotic stimuli, including chemotherapy. Moreover, our results
suggest that the pathways regulating anoikis resistance and chemotherapy resistance might involve
the action of different mediators.
Background
During normal organ development apoptosis provides an
efficient mechanism whereby unwanted cells are "dis-
cretely" eliminated. The functions that ensure proper acti-
vation of apoptosis are somehow lost during
tumorigenesis, allowing cancer cells to proliferate indefi-
nitely and in an uncontrolled fashion[1,2].
Apoptosis is triggered by several stimuli including
hypoxia, radiation-induced DNA damage, oxidative
stress, and lack of attachment. The term anoikis defines
the type of apoptosis induced after proper adherence to
the extracellular matrix (ECM) is denied[3,4]. Attachment
to the ECM is mainly mediated by integrins; a family of
heterodimeric transmembrane receptors composed of an
alpha and a beta chain. In response to physiological clues,
bidirectional integrin signaling mediates cell
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differentiation, proliferation, homing, migration and sur-
vival[5,6]. Integrins lack kinase domains; they signal by
associating in complexes with other mediators such as
FAK, ILK, Src, Shc, Syk, and paxillin [7-13]. Anoikis resist-
ant tumor cells have circumvented the death signals gen-
erated by the lack of attachment affording them increased
survival times while migrating to secondary sites. Thus
resistance to anoikis has been regarded as a crucial step
during tumorigenesis [14-16]. Our previous work has
shown that human osteosarcoma cells, SAOS, are sensi-
tive to anoikis[17]. However, anoikis resistance can be
driven in originally sensitive clones by alternating culture
cycles under adhered and suspended conditions. This
resistant phenotype is stable and indicates that the proc-
esses of de-adhesion or exposure to a non-adhesive envi-
ronment acts as a driving force towards anoikis
resistance[18].
While the precise role of anoikis resistance in osteosar-
coma progression is still unclear, chemoresistance contin-
ues to be an important problem in the clinic. Despite
significant advances in the treatment of osteosarcoma, the
prognosis of patients with metastasis at presentation
remains poor, with an overall survival of 55% after aggres-
sive chemotherapy and surgery[19,20]. Historically,
resistance to chemotherapy has been attributed to the
overexpression of genes encoding cellular efflux
pumps[21]. Recent studies have shown that the action of
many anti-cancer agents results in apoptosis, therefore
alterations in the apoptotic pathway may also confer
multidrug resistance [22-24]. Since the general acquisi-
tion of apoptosis resistance would affect both de-adhe-
sion and chemotherapy-induced cell death, we
investigated whether acquisition of anoikis resistance
conferred general resistance to other apoptotic inducers or
was independent of these other apoptotic pathways.
Methods
Cell culture and reagents
The parental human osteosarcoma cell lines SAOS-2
(SAOSp) and TE-85 (TE-85p) were obtained from the
American Type Culture Collection (Manassas, VA).
SAOSp and TE-85p cells were maintained in Eagle's MEM
(BioWhittaker, Walkersville, MD), supplemented with
10% fetal bovine serum (BioWhittaker, Walkersville,
MD), 2 mM L-glutamine, 1 mM sodium pyruvate and
non-essential amino acids (Sigma, St. Louis, MO).
Anoikis resistant SAOS (SAOSar) and TE-85 (TE-85ar)
cells were generated by sequential cycles of culture on
untreated (adhered) and poly-HEMA treated cell culture
wells (suspended)[18]. The resulting variants were main-
tained in culture under adhered conditions. Poly-HEMA
was prepared by dissolving it in 95% ethanol to a concen-
tration of 50 mg/ml. Poly-HEMA was added to cell culture
wells at a density of 5 mg/cm2 and allowed to dry over-
night, under sterile conditions in a laminar flow hood.
Etoposide, vinblastine and paclitaxel were purchased
from Sigma, St. Louis, MO. Cisplatin was purchased from
Bristol-Myers Squibb Company, Princeton, NJ. Adriamy-
cin was purchased from GensiaSicor™ Pharmaceuticals,
Irvine, CA. In vitro LD50 for each agent was determined.
One in vitro LD50 is defined as the dose required to induce
apoptosis in approximately 50% of the cells in 24 hr of
culture.
Live/Dead cytotoxicity assay
SAOSp and SAOSar were cultured under suspended con-
ditions (poly-HEMA treated cell culture wells) for 24 h.
After culture cells were washed with PBS, and pellets
resuspended in 250 µl of PBS containing 2 µM Calcein-
AM and 8 µM ethidium homodimer-1 (Molecular Probes,
Eugene, OR). Cells were incubated at room temperature
for 15 minutes and visualized using a fluorescent inverted
microscope.
Apoptosis analyses
Cell cycle/apoptosis analyses were performed using pro-
pidiumiodide (PI) staining with subsequent FACS analy-
sis. 5 × 105 cells/well were cultured either on plastic or
poly-HEMA treated 6-well tissue culture plates with or
without the metabolic inhibitors and drugs for 24 hrs at
37°C in a 5% CO2 atmosphere. After incubation, adher-
ent cells were detached with trypsin (0.5% trypsin/0.1%
EDTA in PBS). Detached and suspended cells were har-
vested in complete EMEM medium and centrifuged at 500
g for 10 min. Pellets were washed with PBS and fixed with
ice cold 75% ethanol overnight at 4°C. After fixation, cells
were washed with PBS and stained with 500 µl of PI solu-
tion (50 µg/ml in PBS) containing 25 µg/ml of RNase.
Cells were incubated at 37°C for 30 min and analyzed by
flow cytometry on an Epics Profile flow cytometer (Coul-
ter, Miami, FL). Apoptosis was also assayed by Annexin-
FITC/PI staining following manufacturer instructions
(Trevigen, Inc. Gaithersburg, MD). Briefly, treated or
untreated cells were collected and washed in cold PBS.
Cells were incubated for 15 min at room temperature in
the presence of 1 µl Annexin V-FITC, 1 µl of propidium
iodide and 98 µl of 1x binding buffer (all reagents pro-
vided by the manufacturer). After incubation, 400 µl of 1X
binding buffer was added to each tube, and cells were ana-
lyzed by flow cytometry.
Results
Parental human osteosarcoma SAOS-2 cells (SAOSp)
undergo apoptosis after adherence to the ECM is denied
(anoikis) by culture in poly-HEMA treated cell culture
wells. An anoikis resistant subline (SAOSar) has been gen-
erated after sequential cycles of culture under suspended
and adhered conditions. This stable phenotype is not the
result of mere selection of pre-existing anoikis resistantBMC Cancer 2005, 5:39 http://www.biomedcentral.com/1471-2407/5/39
Page 3 of 10
(page number not for citation purposes)
sub-populations, since anoikis resistant cells can be
derived from anoikis sensitive clonal populations[18]. Fig
1 panel A shows the results of a Live/Dead™ assay of
SAOSp and SAOSar cells cultured in poly-HEMA coated
wells for 24 hr. After incubation, cells were stained with a
mixture of calcein-AM and ethidium homodimer-1 (see
SAOSp cells undergo anoikis after culture under suspended conditions Figure 1
SAOSp cells undergo anoikis after culture under suspended conditions. After culture under suspended conditions 
for 24 h SAOSp and SAOSar cell viability was assayed using a Live/Dead™ assay. Panel A shows a larger fraction of SAOSp cells 
stained red (dead) than of SAOSar cells (majority stained green). Apoptosis was quantitated by PI (panel B) or Annexin V-FITC/
PI (panel C) staining followed by flow cytometry analyses. Panel B shows a higher percentage of SAOSp (33.3%) cells than of 
SAOSar (8.37%) in the sub-G/0 phase representative of apoptotic cells. Similar results are shown in panel C, in which a higher 
percentage of SAOSp cells (32.6%) than of SAOSar (6.09%) stained positive for Annexin V (top and bottom right quadrants) 
representative of apoptotic cells. Results shown are representative of three independent experiments.
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Materials section). Intracellular esterases in live cells con-
vert non-fluorescent cell-permeant calcein-AM to green
fluorescent calcein. By contrast, in non-viable cells with
damaged membranes, non-permeant ethidium
homodimer-1 enters the cells, and by binding to nucleic
acids the ethidium homodimer-1 produces a bright red
fluorescence. Cells were viewed under a fluorescent
inverted microscope using a longpass filter in order to
simultaneously visualize both green and red fluorescence.
Panel A shows a larger fraction of the parental SAOSp cells
stained red (dead), in comparison with the anoikis resist-
ant SAOSar cells in which the majority of the cells stained
green (live). Under control adherent conditions both
SAOS populations were uniformly alive and stained green
(data not shown). For the quantitative analysis of apopto-
sis, two assays were used, cell cycle analysis and a mem-
brane quality assay. Cell cycle was analyzed by staining
DNA with PI and determining by flow cytometry the per-
centage cells with sub-G/0 content. The membrane qual-
ity was assessed by utilizing Annexin staining to identify
phosphatidylserine and PI to monitor membrane integ-
rity. Figure 1B shows a higher percentage of SAOSp cells
in sub-G/0 phase, indicative of apoptosis (33.3%) than of
SAOSar cells (8.37%) after culture in poly-HEMA treated
plates for 24 h. The same was observed after staining with
Annexin V-FITC/PI and flow cytometry. Figure 1C shows
higher percentage of SAOSp cells (32.6%) than of SAOSar
cells (6.09%) stained positive for Annexin V (top and bot-
tom right quadrants) representative of apoptosis as well.
Thus, SAOSar cells resist apoptosis after attachment to
ECM is denied (anoikis).
We have previously shown that SAOSp and SAOSar cells
attached to the ECM are equally sensitive to induction of
apoptosis and die after treatment with staurosporine,
cycloheximide and hydrogen peroxide[18]. We hypothe-
sized that even though the apoptotic machinery was intact
while cultured under adhered conditions, once the
anoikis resistant SAOSar cells were detached from the
ECM, anti-apoptotic mediators could be activated result-
ing in a more generalized resistance to apoptosis. There-
fore, to reexamine the sensitivity of anoikis resistant cells
to other apoptotic stimuli, SAOSar cells were cultured
under non-adherent conditions and exposed to stau-
rosporine, cycloheximide or hydrogen peroxide. As
shown in Fig. 2, untreated SAOSar cells are resistant to
apoptosis when placed in nonadherent conditions,
whereas staurosporine, cycloheximide, or hydrogen per-
oxide treatment of SAOSar cells results in apoptosis. These
data suggest that the mechanisms conferring resistance to
anoikis do not protect SAOSar cells from apoptosis
induced by other stimuli.
Since the mechanism of action of certain chemotherapy
agents can result in apoptosis we tested whether anoikis
resistant SAOS cells were more resistant to chemotherapy-
induced apoptosis. In vitro LD50 for chemotherapy agents
etoposide, adriamycin, vinblastine, cisplatin and paclit-
axel was determined for both SAOSp and SAOSar cultured
under adhered conditions. Similar doses of the agents
used were required to induce apoptosis in ≈  50% of
SAOSp and SAOSar cells cultured under adhered condi-
tions for 24 h (Fig 3). We then tested whether culture
under suspended conditions would have a chemoprotec-
tive effect in anoikis resistant SAOSar cells. SAOSp and
SAOSar cells placed in suspended conditions (poly-
HEMA coated cultured wells) were treated with in vitro
LD50 of etoposide, adriamycin, vinblastine, cisplatin or
paclitaxel. Apoptosis was assayed by PI and Annexin V-
FITC/PI staining followed by flow cytometry analyses. Fig-
ure 4A shows that the percent of untreated SAOSp cells in
the sub-G/0 phase representative of apoptosis is signifi-
cantly increased in comparison to untreated SAOSar when
cells are placed in suspension conditions. The chemother-
apeutic agents do not appear to have an additive effect. By
contrast, the untreated anoikis resistant SAOSar cells
remain viable when placed in suspension but the cells
retain their sensitivity to the chemotherapeutic agents and
undergo apoptosis. This was corroborated by Annexin V-
FITC/PI staining and flow cytometry analyses. Figure 4B
shows a higher percentage of untreated SAOSp cells posi-
tive for Annexin V/FITC staining (top and bottom right
quadrants) than of untreated SAOSar cells after culture
under suspended conditions for 24 h. Chemotherapy-
treated suspended SAOSp and SAOSar showed similar
percentages of cells stained with Annexin V-FITC indica-
tive of apoptosis.
A second osteosarcoma cell line, TE-85, was used to deter-
mine if chemotherapy sensitivity despite anoikis resist-
ance was unique to SAOS-2 cells or represented a more
generalized phenomenon among osteosarcoma. Anoikis
resistant TE-85 cells (TE-85ar) were generated following
the same procedure used for generating the anoikis resist-
ant SAOSar cells. Suspended anoikis sensitive (TE-85p)
and anoikis resistant (TE-85ar) cells were treated with the
same doses of the same drugs and apoptosis was meas-
ured 24 hr later by PI and Annexin V-FITC/PI staining fol-
lowed by flow cytometry analyses. As with SAOS-2 cells,
untreated TE-85ar cells remained viable after culture in
suspension for 24 hr but retained their sensitivity to
chemotherapy-induced apoptosis at similar levels that of
TE-85p cells. No significant differences among the per-
centages of apoptotic TE-85p or TE-85ar suspended cells
were found after chemotherapy treatment, either by PI
(figure 5A) or by Annexin V-FITC/PI (figure 5B) staining.
These results indicate that resistance to anoikis does not
confer resistance to these chemotherapeutic agents, and
that this trend is not unique to SAOS-2 osteosarcoma cells
but also applies to TE-85 osteosarcoma cells.BMC Cancer 2005, 5:39 http://www.biomedcentral.com/1471-2407/5/39
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Discussion
During tumorigenesis the delicate balance between sur-
vival and cell death is altered. Thus, cancer cells are able to
survive under adverse conditions that normally would
trigger apoptosis such as hypoxia, low glucose, and lack of
attachment.
Until recently it was thought that resistance to chemother-
apy was due to mechanisms that prevented the intake of
the drug or the presence of intracellular detoxificants.
Since the discovery that drug-mediated cell death can be
the result of physiological processes such as apoptosis,
mitotic catastrophe and cellular senescence, resistance to
chemotherapy has been linked to alterations in the path-
ways mediating such processes. [22-26].
Resistance to detachment-induced apoptosis (anoikis) is
known as a important step during metastasis by affording
tumor cells increased survival times while migrating to
secondary sites. However, the relationship between
anoikis resistance and chemotherapy response remains to
be elucidated. Previously, we have shown that anoikis
resistance can be induced in anoikis sensitive human oste-
osarcoma cells, SAOS-2, by exposure to culture in suspen-
sion (poly-HEMA treated culture wells). We also
demonstrated that oxidative damage (H2O2), inhibition
of protein synthesis (cycloheximide) or inhibition of cal-
cium-dependent protein kinases (staurosporine) resulted
in apoptosis of adherent SAOS-2 cells regardless of their
anoikis resistant phenotype[18]. This suggested that
under adhered conditions the apoptotic machinery was
intact.
In this study, we tested whether the anti-apoptotic mech-
anisms that rendered the cells anoikis resistant would be
activated upon detachment from the ECM, resulting in a
more generalized resistance to apoptosis and hence to
chemotherapy. For instance, in acute myelogeneous
leukemia interactions between α 4β 1 integrins and
fibronectin activate the PI3-K/Akt pathway resulting in
resistance to both anoikis and to treatment with daunoru-
bicin or AraC[27]. By contrast, our data suggested that
despite the resistant phenotype and the suspended condi-
tions, apoptosis can still be induced by oxidative damage,
inhibition of protein synthesis or inhibition of calcium-
dependent protein kinases in anoikis resistant SAOSar
Apoptosis can be induced in SAOSar cells while cultured under suspended conditions Figure 2
Apoptosis can be induced in SAOSar cells while cultured under suspended conditions. Apoptosis was triggered in 
suspended anoikis-resistant SAOSar cells by staurosporine-induced inhibition of calcium-dependent protein kinases, by 
cycloheximide-induced inhibition of protein synthesis and by H2O2-induced oxidative damage. Percentage apoptosis was deter-
mined by flow cytometry analyzes after staining with propidium iodide. The percentage of cells in the sub-G/0 phase represent-
ative of apoptotic cells is marked on each histogram. Results shown are representative of three independent experiments.
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cells. Furthermore, anoikis resistant SAOSar cells are
equally sensitive to chemotherapy-induced apoptosis
when compared to anoikis sensitive SAOSp cells under
either suspended or adhered culture conditions. Similar
results were obtained after anoikis sensitive and anoikis
resistant TE-85 cells were treated with the same agents.
The chemotherapeutic agents tested vary widely in their
mode of action; etoposide, adriamycin and cisplatin cause
DNA damage by forming DNA adducts or by inhibiting
topoisomerase II resulting in DNA breaks. Vinblastine
and paclitaxel target the microtubules and are known as
"spindle poisons", however their mode of action is differ-
ent. Vinblastine binds to tubulin dimers preventing the
formation of microtubules and paclitaxel binds to the
microtubules inducing mitotic arrest by excessively stabi-
lizing them. Regardless of their mode of action, under
adhered conditions the in vitro LD50  for etoposide,
Chemosensitivity of SAOSp and SAOSar cells Figure 3
Chemosensitivity of SAOSp and SAOSar cells. In vitro LD50 for chemotherapy agents etoposide (50 µM), adriamycin (1 
µg/ml), vinblastine (1 µg/ml), cisplatin (10 µg/ml) and paclitaxel (100 ug/ml) were determined for SAOSp and SAOSar cells cul-
tured under adhered conditions. Similar chemosensitivity was observed for all agents tested by adhered SAOSp and SAOSar 
cells. Apoptosis was determined by PI staining followed by flow cytometry analyses. Error bars indicate the standard deviation 
of three independent experiments.
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Resistance to anoikis does not confer chemoresistance in SAOS cells Figure 4
Resistance to anoikis does not confer chemoresistance in SAOS cells. Suspended SAOSp and SAOSar cells were 
treated with 1 in vitro LD50 of etoposide, adriamycin, vinblastine, cisplatin or paclitaxel. In Panel A, similar percentages of 
SAOSp or SAOSar cells in the sub-G/0 phase representative of apoptotic cells was found after incubation with the indicated 
agents for 24 h under suspended conditions. Error bars indicate the standard deviation of three independent experiments. 
Panel B shows similar percentages of Annexin V-FITC positive SAOSp or SAOSar suspended cells (top and bottom right quad-
rants) after the same treatments. Data shown is representative of three independent experiments.
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Resistance to anoikis does not confer chemoresistance in TE-85 cells Figure 5
Resistance to anoikis does not confer chemoresistance in TE-85 cells. Suspended TE-85p and TE-85ar cells were 
treated with etoposide, adriamycin, vinblastine, cisplatin or paclitaxel for 24 h and apoptosis was assayed by PI (panel A) or 
Annexin V-FITC/PI (panel B) staining followed by flow cytometry analyses. In panel A similar percentages of TE-85p or TE-85ar 
cells in the sub-G/0 phase representative of apoptotic cells were found after incubation with the indicated agents. Error bars 
indicate the standard deviation of three independent experiments. Panel B shows similar percentages of Annexin V-FITC posi-
tive TE-85p or TE-85ar suspended cells (top and bottom right quadrants) after the same treatments. Data shown is represent-
ative of three independent experiments.
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adriamycin, vinblastine, cisplatin or paclitaxel was similar
for both SAOSp and SAOSar cells. Similar levels of apop-
tosis were found after suspended SAOSp and SAOSar cells
were treated with the same doses of the different agents.
The same was observed after suspended TE-85p and TE-
85ar cells were treated with the same agents. These data
suggest that acquisition of anoikis resistance does not nec-
essarily render osteosarcoma cells resistant to other apop-
totic stimuli including chemotherapy.
The specific mechanisms involved in anoikis resistance
are not completely understood. Overexpression of onco-
genes such as ras, raf, rac and src as well as the deletion of
tumor suppressor genes such as PTEN and p53 have been
associated with resistance to anoikis [28-30]. Recently it
was reported that TrkB, a nerurotrophic tyrosine kinase
receptor, is able to suppress anoikis of non-malignant epi-
thelial cells by activating the PI3-K/Akt pathway[31]. Acti-
vated Akt exerts its anti-apoptotic effect by modulating the
activity of mediators that are directly involved in the
apoptotic cascade or by regulating the transcription of
pro- and anti-apoptotic genes [32-34]. Normal breast epi-
thelial cells expressing constitutively active Akt1 lose their
sensitivity to anoikis and become resistant to apoptosis
after treatment with cisplatin and mitoxantrone[35]. Like-
wise, in pancreatic adenocarcinoma cells increased activ-
ity of Akt in response to overexpression of
carcinoembryionic antigen-related cell adhesion mole-
cule (CEACAM)6 results in resistance to both anoikis and
gemcitabine treatment[36]. In these systems, Akt protects
cells against death induced after DNA damage as well as
death induced by anoikis. In our osteosarcoma model, it
is clear that resistance to anoikis is independent of resist-
ance to other apoptotic inducers. We have recently found
that activation of the PI3-K/Akt pathway is important dur-
ing anoikis resistance (Díaz-Montero CM and McIntyre
BW, unpublished data). Since these cells are still sensitive
to other apoptosis inducing agents, upregulation of Akt is
not sufficient to confer resistance to all apoptotic stimuli.
Furthermore, in breast cancer cell lines SKBR-3 and MDA-
MB-453, anoikis resistance can be restored by induction
of ILK, independently of Akt activity[37]. These different
studies suggest that the mechanisms that confer resistance
to anoikis and/or chemotherapy may be unique to each
type of malignancy. Thus it can be argued that anti-cancer
agents that target apoptosis will be less effective against
malignancies in which the pathways for resistance to both
apoptosis and anoikis overlap. Likewise, therapies that
can inhibit a common apoptosis and anoikis resistance
pathway could be a potent new anti-cancer treatment.
Our work suggests that in at least two human osteosar-
coma cell lines, resistance to anoikis and apoptosis are
regulated by different mediators, and might explain why
anoikis resistant cells are still vulnerable to other apopto-
sis-inducing stimuli. This is a fortunate situation except in
those cases where the tumor cells have detached from the
primary sites and survive because of the induction of
anoikis resistance. In many cases, tumor cells that lose
normal adhesive constraints will enter cell cycle arrest and
thus be refractory to many chemotherapeutic reagents. In
this scenario, the ability to target the anoikis resistance
pathway may provide a new approach for chemotherapy.
In conclusion, in order to effectively target anoikis resist-
ant/migrating metastatic tumor cells the apoptotic path-
ways that are altered and the ones that remain normal
need to be identified. Only then, agents with specific
action against the mediators involved during the relevant
disease stage, i.e. primary vs. metastatic, will become
available as more efficient treatment strategies.
Conclusion
The development of newer and more efficacious treat-
ments against cancer will require the understanding of the
mechanisms behind apoptosis and/or anoikis resistance
in a disease-specific way. We have shown that acquisition
of resistance to anoikis in human osteosarcoma cells does
not necessarily result in a generalized resistance to all
apoptotic stimuli. Thus in this particular system, targeting
the pathways involved might control the spread of anoikis
resistant/migrating metastatic cells.
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